Go Pro
→ SPCX Warning - and Worst News for Stocks in 50 Years (From TradeSmith) (Ad)tc pixel Free TNFA Stock Alerts

TNF Pharmaceuticals (TNFA) Financials

TNF Pharmaceuticals logo
$3.48 +0.03 (+0.87%)
As of 07/15/2026
Compare
Annual Income Statements for TNF Pharmaceuticals

Annual Income Statements for TNF Pharmaceuticals

This table shows TNF Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -9.51 -3.30 -7.37 -10 -3.89 -9.49 -30 -15 -8.22 -27 -15
Consolidated Net Income / (Loss)		 -9.31 -3.30 -7.37 -11 -3.89 -9.49 -30 -15 -4.00 -23 -12
Net Income / (Loss) Continuing Operations		 -9.51 -3.30 -7.37 -10 -3.38 -9.49 -30 -15 -4.00 -23 -12
Total Pre-Tax Income 		-9.58 -3.30 -7.37 -11 -3.38 -9.49 -30 -15 -4.00 -23 -12
Total Operating Income		 -9.68 -3.33 -6.61 -10 -3.47 -9.49 -29 -15 -17 -10 -9.85
Total Gross Profit		 1.16 1.88 0.95 0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 2.12 2.96 3.35 1.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 2.12 2.96 3.35 1.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.95 1.08 2.41 1.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cost of Revenue		 0.95 1.08 2.41 1.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 11 5.21 7.56 10 3.47 9.49 29 15 17 10 9.85
Selling, General & Admin Expense		 4.03 3.01 4.08 5.67 3.37 2.95 6.42 5.52 5.44 4.16 3.74
Research & Development Expense		 1.41 1.19 1.26 1.06 0.00 2.47 6.75 9.07 7.87 3.44 3.47
Other Operating Expenses / (Income)		 2.16 -1.30 - - - 3.20 16 0.00 0.76 1.51 0.46
Other Special Charges / (Income)		 - - 0.00 1.51 0.08 0.86 0.00 0.70 3.05 1.06 2.17
Total Other Income / (Expense), net		 -0.10 0.03 -0.76 -0.43 0.09 0.00 -1.08 0.09 13 -13 -1.78
Interest & Investment Income		 0.10 0.02 0.01 0.15 0.11 0.00 0.05 0.08 0.46 0.35 0.23
Other Income / (Expense), net		 -0.00 0.00 -0.77 -0.94 -0.01 0.00 -1.13 0.00 13 -14 -2.01
Income Tax Expense		 -0.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Preferred Stock Dividends Declared		 - - - - - - - 0.00 4.22 3.80 3.36
Basic Earnings per Share		 ($1.81) ($0.61) ($6.29) ($22.28) ($6.35) - ($0.85) ($11.74) ($5.33) ($1,080.87) ($8.66)
Weighted Average Basic Shares Outstanding		 5.14M 5.43M 1.17M 486.95K 612.67K 28.19M 35.02M 1.29M 1.54M 25.13K 1.73M
Diluted Earnings per Share		 ($1.81) ($0.61) ($6.29) ($22.28) ($6.35) - - ($11.74) ($5.33) ($1,080.87) ($8.66)
Weighted Average Diluted Shares Outstanding		 5.14M 5.43M 1.17M 486.95K 612.67K 28.19M 35.02M 1.29M 1.54M 25.13K 1.73M

Quarterly Income Statements for TNF Pharmaceuticals

This table shows TNF Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 2.88 -4.89 -11 -10 -2.68 -3.14 -1.94 -2.77 -3.71 -6.56 -1.53
Consolidated Net Income / (Loss)		 4.04 -2.36 -9.80 -9.57 -1.93 -2.06 -1.12 -1.80 -2.81 -5.89 -1.24
Net Income / (Loss) Continuing Operations		 4.04 -2.36 -9.80 -9.57 -1.93 -2.06 -1.12 -1.80 -2.81 -5.89 -1.24
Total Pre-Tax Income 		4.04 -2.36 -9.80 -9.57 -1.93 -2.06 -1.12 -1.80 -2.81 -5.89 -1.24
Total Operating Income		 -3.84 -4.91 -2.78 -3.37 -1.83 -2.19 -2.47 -1.87 -1.79 -3.71 -1.86
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Operating Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Operating Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 3.84 4.91 2.78 3.37 1.83 2.19 2.47 1.87 1.79 3.71 1.86
Selling, General & Admin Expense		 1.33 1.24 1.07 1.02 1.10 0.97 0.84 0.89 0.97 1.03 1.07
Research & Development Expense		 1.91 2.96 1.20 0.40 0.71 1.13 1.55 0.87 0.36 0.70 0.51
Other Operating Expenses / (Income)		 0.00 - - 1.51 0.00 - - 0.00 0.46 - 0.22
Other Special Charges / (Income)		 0.60 0.71 0.52 0.44 0.01 0.09 0.08 0.10 0.00 1.99 0.06
Total Other Income / (Expense), net		 7.89 2.54 -7.02 -6.20 -0.10 0.12 1.35 0.08 -1.02 -2.18 0.61
Interest & Investment Income		 0.14 0.12 0.02 0.02 0.16 0.15 0.06 0.06 0.04 0.07 0.08
Other Income / (Expense), net		 7.75 2.43 -7.03 -6.22 -0.27 -0.02 1.28 0.02 -1.06 -2.25 0.53
Income Tax Expense		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Preferred Stock Dividends Declared		 1.16 2.53 1.20 0.78 0.75 1.07 0.81 0.98 0.90 0.67 0.29
Basic Earnings per Share		 $1.84 ($3.17) ($5.14) ($4.54) ($107.62) ($124.79) ($0.36) ($0.18) ($2.50) ($3.79) ($0.19)
Weighted Average Basic Shares Outstanding		 1.56M 1.54M 2.14M 2.28M 24.91K 25.13K 5.35M 15.70M 1.48M 1.73M 8.06M
Diluted Earnings per Share		 $0.37 ($3.17) ($5.14) ($4.54) ($107.62) ($124.79) ($0.36) ($0.18) ($2.50) ($3.79) ($0.19)
Weighted Average Diluted Shares Outstanding		 7.82M 1.54M 2.14M 2.28M 24.91K 25.13K 5.35M 15.70M 1.48M 1.73M 8.06M
Weighted Average Basic & Diluted Shares Outstanding		 50.90M 2.16M 2.31M 2.37M 2.76M 0.00 14.18M 176.62M 4.17M 0.00 7.85M

Annual Cash Flow Statements for TNF Pharmaceuticals

This table details how cash moves in and out of TNF Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.05 -0.33 0.60 0.24 0.96 0.01 0.41 0.19 1.93 -2.51 0.81
Net Cash From Operating Activities		 -5.13 -4.17 -5.08 -8.50 -3.07 -4.66 -20 -12 -13 -8.98 -9.07
Net Cash From Continuing Operating Activities		 -5.13 -4.17 -4.84 -8.82 -2.06 -4.66 -20 -12 -13 -8.98 -9.07
Net Income / (Loss) Continuing Operations		 -9.31 -3.30 -7.37 -11 -2.87 -9.49 -30 -15 -4.00 -23 -12
Consolidated Net Income / (Loss)		 -9.31 -3.30 -7.37 -11 -3.38 -9.49 -30 -15 -4.00 -23 -12
Non-Cash Adjustments To Reconcile Net Income		 3.03 -0.98 2.71 1.42 0.92 3.04 15 0.70 -9.80 15 1.81
Changes in Operating Assets and Liabilities, net		 0.85 -0.21 -0.69 0.68 -0.18 0.57 -5.18 2.23 0.82 -0.92 0.75
Net Cash From Investing Activities		 5.08 3.84 -5.01 -0.36 -3.94 0.00 20 6.91 1.85 -6.10 -8.42
Net Cash From Continuing Investing Activities		 5.08 3.84 -5.01 -0.36 -3.94 0.00 20 6.91 1.85 -6.10 -8.42
Purchase of Investments		 -0.06 -0.04 -7.71 -6.60 -6.70 0.00 -0.01 -4.84 -13 -13 -19
Sale and/or Maturity of Investments		 5.31 4.00 2.75 6.31 2.86 0.00 18 12 15 6.75 13
Other Investing Activities, net		 0.01 - - - -0.10 - - - - 0.00 -2.01
Net Cash From Financing Activities		 0.00 0.00 10 9.11 6.97 4.68 0.07 5.55 13 13 18
Net Cash From Continuing Financing Activities		 0.00 0.00 10 9.11 6.97 4.68 0.07 5.55 13 13 18
Repurchase of Preferred Equity		 - - - - - - - 0.00 -0.09 -0.07 0.00
Payment of Dividends		 - - - - - - - 0.00 -1.45 -1.36 -0.08
Issuance of Preferred Equity		 - 0.00 3.68 0.00 - - - 0.00 15 14 6.65
Issuance of Common Equity		 - 0.00 5.80 1.95 6.97 1.98 0.00 5.55 - 0.00 12
Other Financing Activities, net		 - 0.00 0.98 7.16 0.00 0.00 1.19 - -0.08 0.00 0.00
Cash Interest Paid		 - - 0.00 0.00 0.00 0.00 0.27 0.01 0.00 0.00 0.00
Cash Income Taxes Paid		 - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for TNF Pharmaceuticals

This table details how cash moves in and out of TNF Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 0.20 2.38 -2.46 0.31 0.66 -1.02 -0.10 0.13 6.70 -5.92 0.14
Net Cash From Operating Activities		 -3.16 -1.93 -1.76 -2.67 -2.43 -2.12 -2.64 -2.07 -1.16 -3.20 -3.29
Net Cash From Continuing Operating Activities		 -3.16 -1.93 -1.76 -2.67 -2.43 -2.12 -2.64 -2.07 -1.16 -3.20 -3.29
Net Income / (Loss) Continuing Operations		 4.04 -2.36 -9.80 -9.57 -1.93 -2.06 -1.12 -1.80 -2.81 -5.89 -1.24
Consolidated Net Income / (Loss)		 4.04 -2.36 -9.80 -9.57 -1.93 -2.06 -1.12 -1.80 -2.81 -5.89 -1.24
Non-Cash Adjustments To Reconcile Net Income		 -7.33 -1.72 7.55 6.65 0.39 0.71 -1.20 1.39 -0.24 1.87 -1.02
Changes in Operating Assets and Liabilities, net		 0.13 2.15 0.49 0.25 -0.89 -0.77 -0.31 -1.66 1.90 0.83 -1.02
Net Cash From Investing Activities		 3.36 5.93 0.73 -11 3.09 1.10 2.54 2.20 -1.49 -12 2.97
Net Cash From Continuing Investing Activities		 3.36 5.93 0.73 -11 3.09 1.10 2.54 2.20 -1.49 -12 2.97
Purchase of Investments		 -0.14 -0.12 -0.02 -13 -0.16 -0.15 -5.86 -0.06 -0.04 -13 -0.14
Sale and/or Maturity of Investments		 3.50 6.05 0.75 1.50 3.25 1.25 8.40 2.26 0.55 1.44 3.12
Net Cash From Financing Activities		 - -1.62 -1.43 14 - 0.00 0.00 - 9.35 8.95 0.45
Net Cash From Continuing Financing Activities		 - -1.62 -1.43 14 - 0.00 0.00 - 9.35 8.95 0.45
Repurchase of Preferred Equity		 - -15 -1.36 1.22 0.07 - 0.00 - - - -0.06
Issuance of Common Equity		 - - - - - - 0.00 - - 9.03 0.51
Cash Interest Paid		 - - 0.00 - - - 0.00 - - - 0.00
Cash Income Taxes Paid		 - - 0.00 - - - 0.00 - - - 0.00

Annual Balance Sheets for TNF Pharmaceuticals

This table presents TNF Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 8.27 5.09 9.34 7.81 11 0.68 25 18 18 21 41
Total Current Assets		 6.48 3.19 7.78 6.67 10 0.15 13 5.40 5.82 9.41 17
Cash & Equivalents		 0.40 0.07 0.44 0.18 0.52 0.15 0.56 0.75 2.68 0.17 0.99
Short-Term Investments		 4.03 0.05 5.01 5.27 9.16 0.00 11 4.09 2.24 8.35 15
Accounts Receivable		 0.74 0.66 0.98 0.19 0.00 - - - - - 0.02
Prepaid Expenses		 0.19 0.37 0.40 0.44 0.33 0.00 1.11 0.57 0.89 0.89 0.77
Plant, Property, & Equipment, net		 0.25 0.26 0.24 0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 1.54 1.64 1.33 1.05 0.57 0.53 12 12 12 12 25
Goodwill		 - - - - - 0.00 10 10 10 10 10
Intangible Assets		 1.47 1.30 1.13 0.24 - - - - - 0.00 14
Total Liabilities & Shareholders' Equity		 8.27 5.09 9.34 7.81 11 0.68 25 18 18 21 41
Total Liabilities		 1.67 1.70 1.79 1.97 1.53 5.93 1.17 2.84 5.09 6.70 16
Total Current Liabilities		 1.67 1.70 1.79 1.97 1.53 2.35 1.04 2.77 4.99 6.70 5.53
Accounts Payable		 1.67 1.70 1.79 1.97 0.89 1.80 0.99 2.67 3.72 2.90 2.45
Dividends Payable		 - - - - - - - 0.00 0.27 2.46 0.37
Other Current Liabilities		 - - - - - 0.48 0.05 0.10 1.01 1.34 2.72
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 3.59 0.13 0.08 0.10 0.00 11
Other Noncurrent Operating Liabilities		 - - - - 0.00 0.05 0.13 0.08 - 0.00 11
Commitments & Contingencies		 - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - - - - - - 0.00 6.50 19 12
Total Equity & Noncontrolling Interests		 6.60 3.39 7.55 5.83 9.36 -5.26 24 15 6.27 -3.84 13
Total Preferred & Common Equity		 6.60 3.39 7.55 5.83 9.36 -5.26 24 15 12 9.79 22
Preferred Stock		 0.00 0.00 1.76 0.00 0.00 0.00 0.14 0.14 -5.95 -13 -8.80
Total Common Equity		 6.60 3.39 5.80 5.83 9.36 -5.26 24 15 12 9.65 22
Common Stock		 101 101 111 122 129 43 102 108 114 139 166
Retained Earnings		 -94 -97 -105 -116 -120 -49 -79 -94 -102 -129 -144

Quarterly Balance Sheets for TNF Pharmaceuticals

This table presents TNF Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 22 14 26 24 19 17 37 38
Total Current Assets		 9.74 2.46 14 12 6.78 5.15 11 14
Cash & Equivalents		 0.30 0.23 0.54 1.19 0.07 0.21 6.90 1.13
Short-Term Investments		 8.17 1.51 14 11 5.81 3.61 3.09 12
Accounts Receivable		 - - - - - - - 0.02
Prepaid Expenses		 1.26 0.73 1.29 1.39 0.90 1.34 1.15 0.71
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 12 12 11 11 12 12 26 25
Goodwill		 10 10 10 10 10 10 10 10
Intangible Assets		 - - - - - - - 14
Total Liabilities & Shareholders' Equity		 22 14 26 24 19 17 37 38
Total Liabilities		 5.72 4.25 26 6.99 4.94 5.55 16 15
Total Current Liabilities		 5.70 3.97 5.78 6.99 4.94 5.55 6.53 3.69
Accounts Payable		 2.03 3.86 4.62 4.16 2.59 2.68 3.18 1.38
Dividends Payable		 0.20 0.05 0.78 1.50 2.29 2.84 0.09 0.59
Other Current Liabilities		 3.46 0.07 0.06 1.33 0.05 0.03 3.26 1.71
Total Noncurrent Liabilities		 0.02 0.28 20 0.00 0.00 0.00 9.38 11
Other Noncurrent Operating Liabilities		 0.02 0.28 - - - - 9.38 11
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 0.61 4.88 0.28 0.28 5.15 6.32 19 12
Total Equity & Noncontrolling Interests		 16 5.36 0.10 17 8.69 5.28 2.82 12
Total Preferred & Common Equity		 16 9.94 0.10 17 8.69 5.28 14 21
Preferred Stock		 0.14 -4.43 0.14 0.14 0.14 0.14 -11 -8.80
Total Common Equity		 15 9.79 -0.05 17 8.55 5.13 14 21
Common Stock		 112 123 123 143 140 139 152 166
Retained Earnings		 -97 -113 -123 -126 -131 -134 -138 -146

Annual Metrics And Ratios for TNF Pharmaceuticals

This table displays calculated financial ratios and metrics derived from TNF Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 5,144,837.00 5,452,545.00 19,841,104.00 12,474,028.00 12,520,208.00 8,859,868.00 37,639,912.00 39,470,009.00 50,900,715.00 2,755,067.00 4,166,760.00
DEI Adjusted Shares Outstanding		 4.00 5.00 17.00 87.00 87.00 1,477.00 12,547.00 13,157.00 16,967.00 27,551.00 4,166,760.00
DEI Earnings Per Adjusted Shares Outstanding		 -2,378,464.75 -660,707.60 -433,312.35 -120,600.46 -44,692.52 -6,423.71 -2,382.17 -1,155.08 -484.36 -985.85 -3.60
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -52.23% 39.99% 13.30% -50.35% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -229.02% 67.93% -136.28% -51.37% 68.29% -142.56% -254.31% 47.90% 70.84% -432.17% 50.01%
EBIT Growth		 -202.48% 65.66% -121.95% -49.04% 68.30% -172.12% -215.53% 48.96% 70.84% -432.17% 50.01%
NOPAT Growth		 -202.18% 65.62% -98.69% -52.11% 65.49% -173.26% -203.64% 46.95% -12.04% 40.61% 3.16%
Net Income Growth		 -196.28% 64.52% -122.98% -47.28% 64.16% -144.01% -215.03% 49.15% 73.68% -483.99% 50.22%
EPS Growth		 -174.24% 66.30% -122.98% -47.28% 71.50% 0.00% 0.00% 0.00% 73.68% -483.99% 99.20%
Operating Cash Flow Growth		 -316.52% 18.69% -21.74% -67.35% 63.84% -51.70% -318.49% 37.13% -5.79% 30.85% -0.99%
Free Cash Flow Firm Growth		 -28.79% 11.60% -1.42% -53.38% 69.70% -227.71% -516.49% 73.99% -38.66% 34.77% 1.58%
Invested Capital Growth		 -57.22% 50.04% -35.59% -81.98% -216.10% -309.25% 687.99% -21.05% -2.91% 6.67% 7.46%
Revenue Q/Q Growth		 -31.62% 6.65% 9.30% -28.36% -100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -45.98% 48.21% -70.18% 1.33% 46.66% 5.13% -4.62% -3.89% 23.04% 1.11% -46.27%
EBIT Q/Q Growth		 -43.31% 45.41% -66.01% 1.40% 46.48% -8.73% -5.77% -3.89% 23.04% 1.11% -46.27%
NOPAT Q/Q Growth		 -43.33% 45.34% -48.34% 3.12% 37.33% -8.53% -5.21% -5.34% -6.87% 21.10% -18.33%
Net Income Q/Q Growth		 -40.09% 42.89% -65.88% 1.67% 39.12% -2.49% -5.92% -3.44% 25.68% 1.27% -49.13%
EPS Q/Q Growth		 -38.17% 42.99% -65.88% 1.67% 43.00% 0.00% 0.00% -3.44% 25.68% 1.27% -11.17%
Operating Cash Flow Q/Q Growth		 -55.40% 10.55% -18.30% -16.65% 41.01% -19.06% -22.34% 17.28% 2.37% -2.14% -13.51%
Free Cash Flow Firm Q/Q Growth		 3.94% 9.12% -11.99% -2.85% 40.67% -0.82% -13.54% 22.19% -50.28% 15.76% 30.37%
Invested Capital Q/Q Growth		 -47.89% -11.15% -42.39% -75.58% -212.92% -265.88% 17.46% -14.20% 27.99% 35.03% -18.48%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 55.05% 63.42% 28.28% 7.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -443.66% -101.62% -211.92% -646.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -457.78% -112.42% -197.15% -604.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -457.85% -112.30% -220.00% -660.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -440.27% -111.57% -219.58% -651.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 97.19% 100.00% 100.00% 100.00% 114.99% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 98.94% 99.35% 99.81% 98.63% 96.98% 100.00% 99.84% 99.45% 89.78% 98.52% 98.10%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -186.66% -85.65% -172.50% -567.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -150.83% -42.86% -74.28% -497.69% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 99.67% 19.52% 37.84% 405.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -86.99% -66.13% -134.66% -162.09% -51.20% -463.03% -325.06% -79.27% -29.12% -169.93% -58.95%
Cash Return on Invested Capital (CROIC)		 -106.51% -125.68% -129.20% -428.60% 0.00% 0.00% -307.47% -89.39% -142.55% -91.34% -83.95%
Operating Return on Assets (OROA)		 -77.71% -49.79% -102.34% -128.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -74.73% -49.47% -102.15% -126.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -86.99% -66.13% -113.06% -140.84% -51.20% -463.03% -322.50% -78.67% -28.39% -135.17% -46.71%
Return on Equity Simple (ROE_SIMPLE)		 -141.02% -97.52% -97.53% -185.97% -41.56% 180.48% -126.40% -103.42% -32.34% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.78 -2.33 -4.63 -7.04 -2.43 -6.64 -20 -11 -12 -7.12 -6.89
NOPAT Margin		 -320.44% -78.69% -138.00% -422.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -35.83% -42.79% -98.22% -69.82% -19.12% -89.80% -202.49% -46.40% 145.28% -302.99% -44.07%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -191.06% 185.45% -53.82%
Cost of Revenue to Revenue		 44.95% 36.58% 71.72% 92.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 190.52% 101.62% 121.69% 340.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 66.52% 40.15% 37.57% 63.84% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 512.82% 175.84% 225.43% 611.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -9.68 -3.33 -7.38 -11 -3.49 -9.49 -30 -15 -4.46 -24 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.38 -3.01 -7.11 -11 -3.41 -8.28 -29 -15 -4.46 -24 -12
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.94 3.05 0.22 2.26 0.21 0.00 9.03 3.07 0.98 0.30 0.32
Price to Tangible Book Value (P/TBV)		 1.21 4.95 0.27 2.36 0.21 0.00 16.32 11.02 6.93 0.00 0.00
Price to Revenue (P/Rev)		 2.94 3.48 0.37 7.93 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.82 3.12 0.00 20.45 0.00 0.00 18.82 4.60 0.94 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.85 3.44 0.00 4.65 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 -0.69 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 -0.67 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.66 -0.46 -0.51 -0.81 -1.00 -1.55 -0.52 -0.51 -0.40 -0.39 -0.54
Leverage Ratio		 1.16 1.34 1.32 1.28 1.23 2.82 1.39 1.10 1.29 1.43 1.59
Compound Leverage Factor		 1.15 1.33 1.32 1.26 1.19 2.82 1.38 1.10 1.16 1.41 1.56
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% -218.14% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% -4.27% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% -213.86% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 23.24% 0.00% 0.00% 0.00% 0.61% 0.98% -46.59% -91.60% -35.59%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 50.89% 126.08% 48.20%
Common Equity to Total Capital		 100.00% 100.00% 76.76% 100.00% 100.00% 318.14% 99.39% 99.02% 95.71% 65.53% 87.39%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.44 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.42 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.43 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.54 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.52 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.53 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -16.61 -24.41 -16.78 -20.45 -14.70 -145.19 101.37 -0.76 -7.35 -11.68 -5.28
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 16.04% 13.11% 0.00% 0.00% 0.79% 0.75% 2.52% 20.45% 20.77%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.88 1.88 4.36 3.38 6.74 0.06 12.18 1.95 1.17 1.40 3.00
Quick Ratio		 3.09 0.46 3.60 2.86 6.33 0.06 11.12 1.75 0.99 1.27 2.86
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.87 -3.42 -3.47 -5.32 -1.61 -5.28 -33 -8.47 -12 -7.66 -7.54
Operating Cash Flow to CapEx		 -4,543.87% -3,384.52% -9,320.66% -12,464.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.17 0.44 0.47 0.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 1.51 4.25 4.10 2.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.93 0.68 1.61 2.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 9.35 11.60 13.57 10.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.59 0.64 1.38 0.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 241.26 85.87 89.12 127.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 390.95 533.84 226.34 181.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 615.60 567.20 264.14 445.91 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 16.61 52.51 51.32 -136.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2.18 3.26 2.10 0.38 -0.44 -1.80 11 8.36 8.12 8.66 9.30
Invested Capital Turnover		 0.58 1.09 1.25 1.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -2.91 1.09 -1.16 -1.72 -0.82 -1.36 12 -2.23 -0.24 0.54 0.65
Enterprise Value (EV)		 1.79 10 -2.44 7.75 -7.72 60 199 38 7.60 -0.55 -5.77
Market Capitalization		 6.22 10 1.26 13 1.96 56 212 45 12 2.89 6.90
Book Value per Share		 $1.28 $0.62 $0.58 $0.47 $0.75 ($0.59) $0.62 $0.37 $0.24 $3.50 $5.19
Tangible Book Value per Share		 $1.00 $0.38 $0.47 $0.45 $0.75 ($0.59) $0.35 $0.10 $0.03 ($0.31) ($0.71)
Total Capital		 6.60 3.39 7.55 5.83 9.36 -1.65 24 15 13 15 25
Total Debt		 0.00 0.00 0.00 0.00 0.00 3.60 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 3.53 0.00 0.00 0.00 0.00 0.00
Net Debt		 -4.43 -0.12 -5.45 -5.45 -9.68 3.46 -13 -6.34 -4.92 -8.52 -16
Capital Expenditures (CapEx)		 0.11 0.12 0.05 0.07 -0.01 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.39 1.37 0.54 -0.76 -0.90 -2.28 0.07 -2.20 -4.09 -5.81 -4.74
Debt-free Net Working Capital (DFNWC)		 4.81 1.49 5.99 4.70 8.78 -2.13 12 2.63 0.83 2.71 11
Net Working Capital (NWC)		 4.81 1.49 5.99 4.70 8.78 -2.20 12 2.63 0.83 2.71 11
Net Nonoperating Expense (NNE)		 2.53 0.97 2.74 3.81 1.46 2.85 9.72 4.50 -7.99 16 4.73
Net Nonoperating Obligations (NNO)		 -4.43 -0.12 -5.45 -5.45 -9.80 3.46 -13 -6.34 -4.66 -6.06 -15
Total Depreciation and Amortization (D&A)		 0.30 0.32 0.27 0.24 0.07 1.21 0.61 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 18.21% 46.16% 16.12% -45.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 227.53% 50.31% 178.58% 281.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 227.53% 50.31% 178.58% 281.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($347.52) ($117.12) ($117.12) ($23.76) ($6.35) ($2.49) $0.00 ($11.70) ($5.33) ($1,115.00) ($8.66)
Adjusted Weighted Average Basic Shares Outstanding		 28.26K 28.28K 426.95K 520.11K 2.70M 16.65M 38.06M 1.29M 1.54M 24.37K 1.73M
Adjusted Diluted Earnings per Share		 ($347.52) ($117.12) ($117.12) ($23.76) ($6.35) ($2.49) $0.00 $0.00 ($5.33) ($1,115.00) ($8.66)
Adjusted Weighted Average Diluted Shares Outstanding		 28.26K 28.28K 426.95K 520.11K 2.70M 16.65M 38.06M 1.32M 1.54M 24.37K 1.73M
Adjusted Basic & Diluted Earnings per Share		 ($347.52) ($117.12) ($117.12) ($23.76) ($6.35) ($2.49) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 26.78K 28.28K 49.45K 457.24K 612.67K 7.05M 35.02M 1.32M 2.16M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -6.45 -2.33 -4.63 -5.99 -2.38 -6.04 -20 -10 -9.85 -6.38 -5.37
Normalized NOPAT Margin		 -305.01% -78.69% -138.00% -359.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -453.00% -111.57% -219.58% -651.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -36.30% -5.81% -0.67%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -36.30% -5.81% -0.67%

Quarterly Metrics And Ratios for TNF Pharmaceuticals

This table displays calculated financial ratios and metrics derived from TNF Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 44,930,389.00 50,900,715.00 2,157,632.00 2,307,632.00 2,370,423.00 2,755,067.00 2,755,067.00 14,184,088.00 176,615,658.00 4,166,760.00 4,166,760.00
DEI Adjusted Shares Outstanding		 14,977.00 16,967.00 21,576.00 23,076.00 23,704.00 27,551.00 27,551.00 141,841.00 1,766,157.00 4,166,760.00 4,166,760.00
DEI Earnings Per Adjusted Shares Outstanding		 192.62 -288.30 -509.91 -448.21 -113.08 -113.82 -70.35 -19.55 -2.10 -1.57 -0.37
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 205.28% 34.98% -538.51% -120.77% -153.62% 10.76% 87.89% 80.66% -36.02% -169.47% -11.47%
EBIT Growth		 205.28% 34.98% -538.51% -120.77% -153.62% 10.76% 87.89% 80.66% -36.02% -169.47% -11.47%
NOPAT Growth		 -47.97% -28.90% -7.50% 41.72% 66.74% 55.41% 11.23% 44.43% 2.03% -69.69% 24.95%
Net Income Growth		 209.46% 36.90% -548.27% -129.52% -147.72% 12.66% 88.52% 81.22% -45.71% -185.57% -10.49%
EPS Growth		 209.46% 36.90% -328.33% -40.99% -147.72% 12.66% 88.52% 96.04% 97.68% 96.96% 47.22%
Operating Cash Flow Growth		 80.22% 14.04% 55.76% 31.92% 23.02% -9.74% -50.25% 22.60% 52.25% -50.87% -24.48%
Free Cash Flow Firm Growth		 86.75% -631.28% -233.79% -265.91% -205.96% 35.04% 74.33% 51.70% -363.72% -56.50% 31.46%
Invested Capital Growth		 -34.92% -2.91% 396.61% 568.99% 1.11% 6.67% 19.94% 56.07% 78.00% 7.46% 10.29%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 189.90% -163.51% -296.03% 2.36% 78.16% -5.69% 46.24% -55.85% -53.60% -109.39% 77.76%
EBIT Q/Q Growth		 189.90% -163.51% -296.03% 2.36% 78.16% -5.69% 46.24% -55.85% -53.60% -109.39% 77.76%
NOPAT Q/Q Growth		 5.05% 10.58% 43.27% -21.01% 45.82% -19.90% -12.93% 24.24% 4.48% -107.66% 50.05%
Net Income Q/Q Growth		 197.01% -158.46% -314.63% 2.39% 79.83% -6.99% 45.51% -59.70% -56.52% -109.68% 78.92%
EPS Q/Q Growth		 197.01% -158.46% -62.15% 11.67% 79.83% -6.99% 45.51% 50.00% -1,288.89% -51.60% 94.99%
Operating Cash Flow Q/Q Growth		 19.48% 38.77% 9.08% -51.86% 8.94% 12.72% -24.49% 21.77% 43.82% -175.78% -2.71%
Free Cash Flow Firm Q/Q Growth		 -106.88% -624.38% -319.25% 20.63% 87.31% -53.80% -65.64% -49.34% -21.88% 48.09% 27.46%
Invested Capital Q/Q Growth		 536.59% 27.99% 5.38% -20.35% -5.87% 35.03% 18.48% 3.65% 7.35% -18.48% 21.60%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 103.56% 95.33% 99.81% 99.78% 92.17% 93.30% 94.56% 96.89% 98.74% 98.87% 93.73%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -31.26% -29.12% -101.36% -297.63% -142.68% -169.93% -121.95% -115.40% -40.64% -58.95% -62.58%
Cash Return on Invested Capital (CROIC)		 -97.17% -142.55% -275.46% -274.50% -142.60% -91.34% -91.49% -110.89% -121.48% -83.95% -69.70%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -30.44% -28.39% -95.06% -264.21% -137.62% -135.17% -92.86% -48.98% -32.62% -46.71% -48.55%
Return on Equity Simple (ROE_SIMPLE)		 -34.72% 0.00% -123.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.84 -3.44 -1.95 -2.36 -1.28 -1.53 -1.73 -1.31 -1.25 -2.60 -1.30
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 85.93% 19.51% -84.51% -220.88% -6.38% -9.93% 22.96% 17.78% -15.18% -30.67% 0.70%
Return On Investment Capital (ROIC_SIMPLE)		 - -54.77% -36.36% -2,411.69% -7.62% 39.92% -19.91% -24.84% -44.46% -20.30% -11.03%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 3.90 -2.48 -9.82 -9.59 -2.09 -2.21 -1.19 -1.85 -2.85 -5.96 -1.33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 3.90 -2.48 -9.82 -9.59 -2.09 -2.21 -1.19 -1.85 -2.85 -5.96 -1.33
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 9.04 0.98 0.52 0.00 0.24 0.30 21.91 0.38 0.43 0.32 1.35
Price to Tangible Book Value (P/TBV)		 28.59 6.93 0.00 0.00 0.66 0.00 0.00 0.00 1.67 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 20.45 0.94 0.45 0.00 0.00 0.00 18.20 0.43 0.29 0.00 1.59
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.53 -0.40 -0.77 -0.55 -0.62 -0.39 -0.22 0.46 -0.54 -0.54 -0.43
Leverage Ratio		 1.22 1.29 1.77 4.34 1.38 1.43 1.38 3.63 1.60 1.59 1.52
Compound Leverage Factor		 1.26 1.23 1.77 4.33 1.27 1.33 1.31 3.52 1.58 1.57 1.43
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.90% -46.59% -43.28% 37.80% 0.85% -91.60% 1.04% 1.25% -53.29% -35.59% -37.14%
Noncontrolling Interests to Total Capital		 3.78% 50.89% 47.66% 74.42% 1.63% 126.08% 37.21% 54.51% 86.79% 48.20% 50.30%
Common Equity to Total Capital		 95.32% 95.71% 95.63% -12.22% 97.52% 65.53% 61.74% 44.24% 66.50% 87.39% 86.84%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 9.16 -6.98 -12.55 -7.26 -7.03 -8.37 12.89 -11.10 -5.04 -4.81 -3.98
Noncontrolling Interest Sharing Ratio		 2.61% 2.52% 6.21% 11.23% 3.54% 20.45% 23.85% 57.56% 19.71% 20.77% 22.42%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.71 1.17 0.62 2.48 1.72 1.40 1.37 0.93 1.71 3.00 3.71
Quick Ratio		 1.49 0.99 0.44 2.52 1.74 1.27 1.19 0.69 1.53 2.86 3.52
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.44 -3.19 -13 -11 -1.35 -2.07 -3.44 -5.13 -6.25 -3.25 -2.35
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 6.34 8.12 8.55 6.81 6.41 8.66 10 11 11 9.30 11
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -3.40 -0.24 11 8.26 0.07 0.54 1.70 3.82 5.00 0.65 1.06
Enterprise Value (EV)		 130 7.60 3.83 -9.95 -7.68 -0.55 187 4.58 3.30 -5.77 18
Market Capitalization		 139 12 5.12 4.19 4.03 2.89 187 1.93 6.16 6.90 28
Book Value per Share		 $0.34 $0.24 $0.19 ($0.02) $7.02 $3.50 $3.10 $0.36 $0.08 $5.19 $4.94
Tangible Book Value per Share		 $0.11 $0.03 ($0.01) ($4.57) $2.59 ($0.31) ($0.71) ($0.38) $0.02 ($0.71) ($0.96)
Total Capital		 16 13 10 0.38 17 15 14 12 21 25 24
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -9.97 -4.92 -1.74 -15 -12 -8.52 -5.88 -3.81 -10.00 -16 -13
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.43 -4.09 -3.25 -5.99 -7.10 -5.81 -4.04 -4.21 -5.38 -4.74 -2.96
Debt-free Net Working Capital (DFNWC)		 4.04 0.83 -1.51 8.57 5.04 2.71 1.84 -0.40 4.61 11 10
Net Working Capital (NWC)		 4.04 0.83 -1.51 8.57 5.04 2.71 1.84 -0.40 4.61 11 10
Net Nonoperating Expense (NNE)		 -7.89 -1.07 7.85 7.21 0.65 0.53 -0.61 0.49 1.56 3.29 -0.06
Net Nonoperating Obligations (NNO)		 -9.77 -4.66 -1.69 6.43 -11 -6.06 -3.59 -0.97 -9.91 -15 -12
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.06 ($3.17) ($5.14) ($4.54) ($111.00) ($12,479.00) ($36.00) ($0.18) ($2.50) ($3.79) ($0.19)
Adjusted Weighted Average Basic Shares Outstanding		 44.95M 1.54M 2.14M 2.28M 24.15K 251.00 53.50K 15.70M 1.48M 1.73M 8.06M
Adjusted Diluted Earnings per Share		 $0.06 ($3.17) ($5.14) ($4.54) ($111.00) ($12,479.00) ($36.00) ($0.18) ($2.50) ($3.79) ($0.19)
Adjusted Weighted Average Diluted Shares Outstanding		 44.95M 1.54M 2.31M 2.28M 24.15K 251.00 53.50K 15.70M 1.48M 1.73M 8.06M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($3.17) $0.00 $0.00 $0.00 ($12,479.00) $0.00 $0.00 $0.00 ($3.79) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 50.90M 2.16M 2.31M 2.37M 27.55K 0.00 141.84K 176.62M 4.17M 0.00 7.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.27 -2.94 -1.59 -2.05 -1.27 -1.47 -1.67 -1.24 -1.25 -1.21 -1.26
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% -36.30% 0.00% -15.50% 0.00% -5.81% 0.00% -0.98% 0.00% -0.67% 0.00%
Augmented Payout Ratio		 0.00% -36.30% 0.00% -15.50% 0.00% -5.81% 0.00% -0.98% 0.00% -0.67% 0.00%

Financials Breakdown Chart

TNF Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, TNF Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

TNF Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$11.63 million in 2025, rising from -$9.31 million in 2015. The previous period was -$23.36 million in 2024. Check out TNF Pharmaceuticals' forecast to explore projected trends and price targets.

TNF Pharmaceuticals' total operating income in 2025 was -$9.85 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $9.85 million

Over the last 10 years, TNF Pharmaceuticals' total revenue changed from $2.12 million in 2015 to $0.00 in 2025, a change of -100.0%.

TNF Pharmaceuticals' total liabilities were at $16.44 million at the end of 2025, a 145.3% increase from 2024, and a 885.2% increase since 2015.

In the past 10 years, TNF Pharmaceuticals' cash and equivalents has ranged from $72.70 thousand in 2016 to $2.68 million in 2023, and is currently $987.00 thousand as of their latest financial filing in 2025.

Over the last 10 years, TNF Pharmaceuticals' book value per share changed from 1.28 in 2015 to 5.19 in 2025, a change of 304.0%.


Related Companies

Financial statements for NASDAQ:TNFA last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel